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Abstract
Background: Vitamin D has significant immunomodulatory effects on both adaptive and innate immune
responses. Observational studies indicate that adults infected with HIV with low vitamin D status may be at
increased risk of mortality, pulmonary tuberculosis, and HIV disease progression. Growing observational evidence
also suggests that low vitamin D status in pregnancy may increase the risk of adverse birth and infant health
outcomes. As a result, antiretroviral therapy (ART) adjunct vitamin D3 supplementation may improve the health of
HIV-infected pregnant women and their children.
Methods/design: The Trial of Vitamins-5 (ToV5) is an individually randomized, double-blind, placebo-controlled trial of
maternal vitamin D3 (cholecalciferol) supplementation conducted among 2300 HIV-infected pregnant women receiving
triple-drug ART under Option B+ in Dar es Salaam, Tanzania. HIV-infected pregnant women of 12–27 weeks gestation are
randomized to either: 1) 3000 IU vitamin D3 taken daily from randomization in pregnancy until trial discharge at
12 months postpartum; or 2) a matching placebo regimen. Maternal participants are followed-up at monthly clinic visits
during pregnancy, at delivery, and then with their children at monthly postpartum clinic visits. The primary efficacy
outcomes of the trial are: 1) maternal HIV disease progression or death; 2) risk of small-for-gestational age (SGA) births;
and 3) risk of infant stunting at 1 year of age. The primary safety outcome of the trial is incident maternal hypercalcemia.
Secondary outcomes include a range of clinical and biological maternal and child health outcomes.
Discussion: The ToV5 will provide causal evidence on the effect of vitamin D3 supplementation on HIV progression and
death, SGA births, and infant stunting at 1 year of age. The results of the trial are likely generalizable to HIV-infected
pregnant women and their children in similar resource-limited settings utilizing the Option B+ approach.
Trial registration: ClinicalTrials.gov identifier: NCT02305927. Registered on 29 October 2014.
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Background
Antiretroviral therapy (ART) is the principal tool utilized
for prevention of mother-to-child transmission (PMTCT)
of human immunodeficiency virus (HIV) worldwide, which
is primarily effective due to its ability to reduce maternal
viral load during antenatal, delivery, and lactation periods
[1]. In 2015 the World Health Organization (WHO) up-
dated their PMTCT guidelines to universally recommend
Option B+ in which all HIV-infected pregnant women initi-
ate lifelong triple-drug ART, irrespective of clinical or im-
munologic status [2]. In addition to avoiding a CD4 T-cell
based ART initiation criterion, additional rationales for util-
izing Option B+ include that pregnant women take triple
antiretrovirals for their own health, ART prevents mother-
to-child transmission of HIV for the current, as well as fu-
ture, pregnancies, and mothers also avoid the risks associ-
ated with starting and stopping antiretrovirals [3]. Due to
evidence from the Malawian experience with Option B+
[4], the HIV care and treatment program in Dar es Salaam,
Tanzania, started utilizing the Option B+ approach in 2013.
The public health approach of Option B+, if universally
implemented, may virtually eliminate mother-to-child HIV
transmission, but will also lead to an estimated 1.5 million
children per year being born HIV-exposed uninfected
(HEU) and exposed to triple antiretrovirals in utero [5]. In
resource-limited settings, HEU children have an estimated
two- to three-times risk of mortality as compared with chil-
dren born to HIV-uninfected women [6, 7]. HEU children
also appear to be at increased risk of poor birth outcomes
and postnatal growth faltering as compared with HIV-
unexposed children [8, 9]. A few potential mechanisms, in-
dependent of maternal sociodemographic differences,
which may lead to increased risk of poor health outcomes
among HEU children include exposure to antiretroviral
drugs, increased exposure to pathogens, and deficits in im-
mune responses to vaccination and pathogens, [8, 10, 11].
There is also growing evidence that exposure to triple anti-
retrovirals in utero among HEU children may lead to in-
creased risk of postnatal growth faltering [8, 12]. A recent
study in Botswana found HEU infants exposed to triple
antiretrovirals in utero had lower length at birth, and at 6
and 24 months of age compared to HEU infants exposed to
zidovudine monotherapy [12]. As a result, low-cost ART
adjunct interventions are needed to improve birth out-
comes and linear growth of HEU children in resource-
limited settings.
Vitamin D is a potent immunomodulator which plays a
prominent role in the control of intracellular pathogens
[13, 14]. Therefore, HIV-infected individuals with low levels
of vitamin D may have poorer control of HIV replication
and immunologic response to other intracellular infections,
notably Mycobacterium tuberculosis [15]. Multiple observa-
tional cohort studies in both high-income and resource-
limited settings have determined that HIV-infected adults
with low vitamin D status are at increased risk of mortality,
incident tuberculosis (TB), and HIV progression [16–19].
To the best of our knowledge, members of our research
group have conducted the only cohort study of vitamin D
and clinical outcomes among HIV-infected pregnant
women [17]. In this study of HIV-infected pregnant Tanza-
nian women conducted prior to the introduction of ART,
women with a serum 25-hydroxyvitamin D (25(OH)D)
concentration < 32 ng/mL in the second trimester (12–27
weeks gestation) had 25% increased risk of progression to
WHO HIV stage III disease, and these morbidity benefits
appeared to increase linearly up to 70 ng/mL [17]. Women
in the highest quintile of 25(OH)D also had 42% lower risk
of all-cause mortality as compared to those in the lowest
quintile. As a result, provision of ART adjunct vitamin D
supplementation may improve the health of HIV-infected
pregnant women, even in equatorial settings where levels of
deficiency may be low.
In addition to the maternal benefits, children born to
HIV-infected mothers with adequate levels of vitamin D
in pregnancy and during lactation may also experience
health benefits. The only published study of maternal vita-
min D in pregnancy and child health outcomes among
HIV-infected pregnant women is the previously men-
tioned cohort study of Tanzanian women who did not re-
ceive ART conducted by members of our group [17, 20].
We found that children born to mothers with low vitamin
D concentrations in the second trimester (25(OH)D <
32 ng/mL) had significantly increased risk of stunting, be-
ing underweight, and reporting cough during their first
5 years of life [21]. There was also some indication that
low vitamin D levels were associated with increased risk
of small-for-gestational age (SGA) infants, but results were
not statistically significant [20].
In contrast to the sparse data among HIV-infected preg-
nant women, a relatively large number of observational
maternal vitamin D studies have been conducted among
HIV-uninfected women, primarily in high-income set-
tings. A meta-analysis of 24 observational studies con-
ducted among HIV-uninfected women determined that
25(OH)D levels < 20 ng/mL were associated with an ap-
proximate 50% increased risk of SGA and preterm deliv-
ery [22]. Despite supportive observational evidence, few
randomized controlled trials (RCTs) of vitamin D supple-
mentation have been published to date [23–27]. A trial
conducted by Brooke and colleagues among 126 pregnant
women of Asian descent in the UK found some indication
that 1000 IU vitamin D/day may decrease the risk of SGA,
but results were not statistically significant [23]. Similar
nonsignificant benefits on SGA were also found in another
small trial conducted among 180 pregnant women in the
UK which utilized a single bolus dose of 200,000 IU vita-
min D or a daily vitamin D3 supplement of 800 IU vitamin
D as compared to placebo [26]. In a recent randomized
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trial conducted among 160 Bangladeshi pregnant women,
infants born to women supplemented with 35,000 IU vita-
min D3 per week in the third trimester of pregnancy had
significantly increased length-for-age z-scores (LAZ) at
1 year of age compared to infants born to mothers receiv-
ing placebo [25]. A small trial of maternal vitamin D sup-
plementation in Iran also determined that pregnant
women with 25(OH)D < 30 ng/mL at 24–26 weeks gesta-
tion randomized to 50,000 IU vitamin D3 per week or
400 IU vitamin D3 per day had significantly increased
birthweight compared to those receiving placebo [24]. A
recent meta-analysis of RCTs found that vitamin D sup-
plementation in pregnancy significantly increased birth
weight and birth length but had no effect on preeclampsia,
gestational diabetes, SGA, preterm birth, and cesarean
section [27]. Overall, small randomized trials suggest that
vitamin D supplementation may significantly improve
some birth outcomes; however, these trials were likely
underpowered to detect moderate differences in maternal
and child health outcomes and their small sample size also
limits the generalizability of their findings.
The WHO currently does not recommend routine
vitamin D supplementation in pregnancy owing to a lack
of sufficient evidence for an effect on maternal and child
health outcomes [28]. In order to address this evidence
gap, we present the protocol for an ongoing randomized,
double-blind, placebo-controlled trial of maternal vita-
min D3 supplementation conducted among HIV-infected
pregnant women in Dar es Salaam, Tanzania.
Methods/design
The Trial of Vitamins-5 (ToV5) is an individually random-
ized, parallel group, double-blind, placebo-controlled trial
of vitamin D3 (cholecalciferol) supplementation conducted
among 2300 HIV-infected pregnant women receiving ART
in Dar es Salaam, Tanzania (ClinicalTrials.gov identifier
NCT02305927). The trial protocol was developed by col-
laborators at the Harvard T.H. Chan School of Public
Health in the United States and Management and Develop-
ment for Health (MDH) and Muhimbili University of
Health and Allied Sciences (MUHAS) in the United Repub-
lic of Tanzania. The ToV5 protocol diagram is presented in
Fig. 1. The schedule of trial enrollment, interventions, and
assessments is presented in Fig. 2. The first participant was
enrolled in the trial in June 2015 and follow-up data collec-
tion will continue through June 2019. This protocol was
written following the Standard Protocol Items: Recommen-
dations for Interventional trials (SPIRIT) checklist (see
Additional file 1).
Primary and secondary objectives
The goal of ToV5 is to investigate vitamin D3 as a simple
and low-cost ART adjunct intervention to improve health
outcomes for HIV-infected pregnant women and their
children. The primary aims of the trial are to determine
the effect of maternal vitamin D3 supplementation starting
in the second trimester and continuing until 12 months
postpartum on: 1) maternal HIV disease progression or
death; 2) risk of small-for-gestational age births (below
tenth percentile birthweight for gestational age by sex
using the Oken standard [29]); and 3) risk of infant stunt-
ing (LAZ < –2) at 12 months of age as compared to a
matching placebo regimen. The secondary aims of the
study are to determine the effect of the maternal vitamin
D3 supplementation regimen on: 1) maternal CD4 T-cell
reconstitution and HIV viral load; 2) maternal immuno-
logic biomarkers (interleukin (IL)-2, IL-12, interferon
(IFN)-γ, and the antimicrobial peptide cathelicidin); 3)
maternal weight gain in pregnancy; 4) maternal depression
and anxiety; 5) maternal hypercalcemia (serum albumin
adjusted calcium > 2.6 mmol/L); 6) miscarriage; 7) still-
birth; 8) preterm birth; 9) birthweight; 10) low birthweight
(<2500 g); 11) mother-to-child transmission of HIV; 12)
infant mortality; 13) infant growth trajectory the first year
of life (LAZ, weight-for-age z-scores (WAZ), and weight-
for-length z-scores (WLZ); 14) infant wasting (WLZ < –2);
15) infant underweight (WAZ < –2); 16) infant morbidities
and hospitalization; 17) infant cognitive, motor, and socio-
emotional development; 18) serum 25(OH)D levels in the
mother and in the infant during the first 12 months of life;
and 19) maternal and infant parathyroid hormone (PTH)
concentrations.
Study population
Women are eligible for ToV5 if they meet all the following
inclusion criteria: 1) aged ≥ 18 years; 2) received an HIV-
positive test; 3) receiving ART; 4) pregnant and of 12–27
weeks gestation (second trimester) as determined by the
report of the last menstrual period (LMP); and 5)
albumin-adjusted calcium levels in the normal physiologic
range (<2.6 mmol/L). Women were excluded if they: 1)
did not intend to stay in Dar es Salaam for 2 years after
enrollment; 2) were enrolled in any other clinical trial; or
3) did not provide informed consent. We do not screen
vitamin D levels at baseline as part of the ToV5 eligibility
criteria due to evidence from our observational cohort
study of HIV-infected Tanzanian pregnant women which
indicated there was no plateau in the beneficial effects of
increased 25(OH)D up to 70 ng/mL [17].
Vitamin D3 and placebo regimen
In the trial, pregnant women are randomized to re-
ceive of one of two regimens: 1) vitamin D3 (cholecal-
ciferol) oral supplements containing 3000 IU taken
daily from randomization at 12–27 weeks gestation
until 12 months postpartum; or 2) a matching pla-
cebo regimen taken daily from randomization until
12 months postpartum.
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The 3000 IU vitamin D3 regimen was selected in
order to sustain 25(OH)D levels > 32 ng/mL for nearly
all pregnant women while having minimal risk of hy-
percalcemia. In a landmark safety and effectiveness
trial of vitamin D3 supplementation conducted by
Hollis and Wagner, pregnant US women were ran-
domized receive 400, 2000, or 4000 IU vitamin D3/
day from 12–16 weeks gestation until delivery [30]. In
this trial the proportion of women reaching a
25(OH)D concentration greater than 32 ng/mL at de-
livery was comparable for women in the 4000 IU
(84%) and the 2000 IU (80%) arms but was signifi-
cantly lower in the 400 IU (52%) arm. There were no
differences in any safety measure between arms and
the Data and Safety Monitoring Board (DSMB) deter-
mined no hypercalcemia events were attributed to
vitamin D supplementation or circulating 25(OH)D
levels. Based on these and other data, the US Insti-
tute of Medicine (IOM) set the tolerable upper intake
limit (UL) of vitamin D3 to 4000 IU/day during preg-
nancy and lactation [31]. In ToV5 we decided to
utilize 3000 IU vitamin D3 per day, as the studies the
IOM used to set the 4000 IU tolerable upper limit
were not conducted among pregnant women residing
equatorially. We also restricted ToV5 enrollment to
12–27 weeks gestation due to a lack of safety data on
the use of 3000 IU daily supplement units before
12 weeks of gestation. Vitamin D3 supplements (cho-
lecalciferol) were chosen over vitamin D2 (ergocalcif-
erol) supplements since vitamin D3 is more effective
in increasing and sustaining circulating 25(OH)D [32].
The vitamin D3 and placebo regimen for ToV5 are
produced in the USA by Tischcon Corp. (Salisbury,
MD) and shipped to Tanzania. There is no
Fig. 1 The Trial of Vitamins-5 (ToV5) flow diagram
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discernible difference between vitamin D3 and pla-
cebo supplements in any manner, including appear-
ance or taste. The placebo inactive ingredients
included maltrin, gelatin, magnesium stearate, and ti-
tanium dioxide. The vitamin D3 and placebo supple-
ments are hard gelatin capsules containing white
powder which weigh on average 467 mg. Both regi-
mens are also stored in identical bottles containing
45 capsules which are prelabeled with the patient
ID. The vitamin D3 and placebo regimens have a
shelf-life of 2 years, and thus two batches are re-
quired to complete the trial. In order to monitor
vitamin D3 composition of the supplements through-
out their shelf-life, Tishcon Corp. will test a random
sample of capsules by high-performance liquid chro-
matography (HPLC) at production and then again at
the end of the shelf-life after return shipping to the
USA from Tanzania.
Sample size
Sample size and power calculations for ToV5 were based
on a two-sided test of proportions and a z-statistic using
the asymptotic variances of the observed proportions
which assumed 1:1 randomization to vitamin D3 and
placebo arms and a nominal Type I error rate (alpha) of
0.05 [33]. We also assumed a 90% retention rate of HIV-
infected mothers until study discharge at 1 year postpar-
tum, 90% retention of birth outcomes (including fetal
loss), and 85% retention of infants to 1 year postpartum
(including fetal loss). We selected a trial sample size of
2300 individuals in order to provide adequate power for
a reasonable range of incidences and effect sizes for the
primary outcomes of maternal HIV progression and
death, SGA births, and infant stunting. Table 1 presents
the statistical power, varying the effect size and inci-
dence of the primary outcomes. We will have > 80%
power to detect an effect size of 0.70 or greater if the
Fig. 2 Schedule of enrollment, interventions, and assessments (SPIRIT Figure). 25(OH)D 25-hydroxyvitamin D, HIV human immunodeficiency virus,
MUAC mid-upper arm circumference, WHO World Health Organization
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incidence of HIV progression or death is 15% over
follow-up as expected. As for the SGA outcome (below
tenth percentile birthweight for gestational age by sex
on Oken standard [29]), a meta-analysis of published
maternal vitamin D3 supplementation trials indicates a
potentially strong effect on SGA with a relative risk of
0.67 (95% confidence interval (CI) 0.40–1.11) [34]. We
will have > 80% power to detect a relative risk on SGA as
low as 0.75, even if the risk of SGA is far lower than ex-
pected and equal to the reference population at 10%. As
for infant stunting, in a recent RCT of multivitamins
conducted among Tanzanian HEU infants, the risk of
stunting at 1 year postpartum was about 20% [35]. As
for the potential effect size of maternal vitamin D3 sup-
plementation on infant stunting, the only randomized
trial to date to examine linear growth was conducted in
Bangladesh and found a large effect size on child stunt-
ing (odds ratio for stunting during first year 0.45, 95%
CI 0.20–1.00) [36]. In ToV5 we will have adequate stat-
istical power for infant stunting even if both the inci-
dence of stunting and the effect size are unexpectedly
smaller at 15% and a relative risk of 0.80, respectively.
Enrollment and follow-up procedures
Screening and randomization procedures
The ToV5 has a two-part screening protocol which is inte-
grated with routine PMTCT visits of the Dar es Salaam
HIV care and treatment program. The trial is conducted at
five PMTCT sites in Dar es Salaam, including Mnazi
Mmoja Hospital, Buguruni Health Center, Mbagala Rangi
Tatu Hospital, Sinza Hospital, and Tabata A Dispensary.
These sites were selected since they are among the largest
PMTCTs in Dar es Salaam in terms of patient numbers ac-
cording to program records. All PMTCT sites are attached
to ANC clinics. Research nurses and clinic staff were uni-
formly trained before the start of the study and have re-
fresher meetings at least every 6 months or as issues arise.
At the first screening visit, research nurses identify HIV-
infected pregnant women and assess eligibility criteria.
Study nurses confirm pregnancy with a urine pregnancy
test and gestational age is assessed through the report of
the last menstrual period. Pregnant women receive HIV
testing as part of routine antenatal care in Tanzania and
women with unknown HIV status receive HIV testing with
two licensed rapid assays [37]. If the HIV rapid assays are
inconclusive (first test positive and second negative), the
first and second HIV rapid assay are repeated following the
same algorithm. If the results are still inconclusive upon re-
peat testing, the pregnant woman is advised that she may
be in the acute HIV infection period and be asked to return
for a repeat HIV testing in 2–4 weeks. Potential participants
self-report the location of their residence and any plans to
move out of the study area in the next year. Pregnant
women who meet all other eligibility for ToV5 screening
are then asked to provide written informed consent for a
blood draw to screen for prevalent hypercalcemia. Serum
calcium and albumin concentrations are assessed with the
Roche Cobas Integra 400 Plus. Albumin-adjusted serum
calcium concentration is then calculated using the follow-
ing equation: calcium (mg/dL) = total calcium (mg/dL) +
0.8 × [4 − albumin (g/dL)] [38]. The results of the albumin-
adjusted calcium screening are returned at a second screen-
ing clinic visit 1–2 weeks after the initial visit and any
participants with above the normal physiologic range of
Table 1 Statistical power for a trial sample size of 2300 with 1:1 randomization to vitamin D3 and placebo arms, and a nominal Type
I error rate (alpha) of 0.05
Hazard ratio (HR) for maternal HIV progression (any increase in WHO HIV stage) or death
Cumulative incidence over average 17 months follow-upa HR = 0.60 HR = 0.65 HR = 0.70
12.5% 95.7% 88.3% 75.5%
15% 98.0% 93.0% 82.3%
17.5% 99.1% 95.8% 87.3%
Relative risk (RR) of small-for gestational age (SGA) birth
Cumulative incidence of SGA in placebo arm RR = 0.65 RR = 0.70 RR = 0.75
10% 98.4% 93.4% 81.2%
12% 99.5% 96.9% 88.3%
14% 99.9% 98.7% 93.0%
Relative risk (RR) of child stunting at 12 months of age (LAZ < –2)
Cumulative incidence of stunting in placebo arm RR = 0.60 RR = 0.70 RR = 0.80
15% >99.9% 98.8% 78.4%
20% >99.9% >99.9% 90.3%
25% >99.9% >99.9% 96.3%
aAssumes the monthly incidence of maternal human immunodeficiency virus (HIV) progression or death is constant during follow-up
LAZ length-for-age z-score, WHO World Health Organization
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albumin-adjusted calcium (>2.6 mmol/L) are diagnosed
with hypercalcemia and are not eligible for ToV5 enroll-
ment. For pregnant women with normal albumin-adjusted
calcium concentrations, study nurses reconfirm enrollment
eligibility, including being within the range of 12–27 weeks
gestation, and written informed consent for trial enrollment
is sought.
Pregnant women who consent for ToV5 enrollment
are individually randomized 1:1 to the vitamin D3 or pla-
cebo arm. Randomization procedures were designed for
complete allocation concealment and blinding of all par-
ticipants, clinic staff, senior research staff, and trial stat-
isticians. Trial arm allocation is performed according to
a computer-generated randomization list (generated off-
site by a nonstudy statistician) of 2300 individuals with
sequence blocks of 10, stratified by study clinic. Two
nonstudy statisticians will hold the randomization list
codes until completion of primary analyses or until re-
quested by the DSMB. The ToV5 DSMB reviews event
rates every 6 months and will recommend any necessary
changes to the trial sample size to maintain statistical
power. All serious adverse events (SAEs) that are at least
possibly related to the study regimen or activities are re-
ported to all Institutional Review Boards within 24 h of
Principal Investigator notification as per regulatory
guidelines. An independent study pharmacist prepares
the vitamin D3 and placebo regimen by labeling bottles
with participant IDs based on the randomization list. At
the randomization visit, allocation concealment is per-
formed by assigning eligible pregnant women who con-
sented for trial randomization to the next available
numeric participant ID which corresponds to a set of
prelabeled regimen bottles with the participant ID. As a
result of these randomization procedures, all trial partic-
ipants, research staff, and trial statisticians are not able
to determine the allocated trial arm for any trial partici-
pant or identify trial participants who are on the same
trial regimen. Allocation is completely concealed.
At the randomization visit, all study participants re-
ceive a full clinical examination from study physicians,
they have their HIV disease stage assessed according to
the WHO criteria, and all comorbidities are treated as
per Tanzanian standard of care [39]. Nurses also admin-
ister a standardized questionnaire to collect information
on sociodemographics, symptoms during the last 30 days
(fever, cough, etc.), depression, anxiety, social support,
and physical activity. The Hopkins Symptom Checklist
(HSCL-25) will be administered to assess symptoms of
depression and anxiety [40]. We have previously vali-
dated the HSCL-25 among Tanzanian women living with
HIV against a diagnosis of a major depressive disorder
by a trained psychiatrist using the Structured Clinical
Interview for the Diagnostic and Statistical Manual of
Mental Disorders, Fourth Edition (DSM-IV) [41]. We
will measure functional dimensions of social support, a
scale based on the Duke University–University of North
Carolina Functional Social Support Questionnaire [42].
Nurses also collect anthropometric measurements in-
cluding height, weight, mid-upper arm circumference
(MUAC), and fundal height. All pregnant women also
have their blood pressure assessed. Participants are also
asked for cell phone numbers and the location of their
home for follow-up visits, given the participant provides
written informed consent. Home visits are conducted by
trained research assistants who receive updated training
on home visits in the context of HIV every 6 months.
The accuracy of home visit information is assessed
through spot checks by clinic supervisors. At the end of
the randomization visit, participants are given a regimen
bottle containing 45 capsules and are told to bring the
bottle and remaining capsules to their next study visit.
Prenatal follow-up visits
All enrolled pregnant woman are seen in the research clinic
every 4 weeks during pregnancy until delivery. Starting at
32 weeks gestation, all women also receive weekly phone
calls and are instructed to call study staff when they go into
labor. At all prenatal visits, study physicians perform a full
clinical examination, assess WHO HIV disease stage, and
treat all comorbidities in accordance with the Tanzanian
standard of care. Nurses collect weight, MUAC, fundal
height, and blood pressure. Study nurses also assess compli-
ance with the trial regimen by counting the number of un-
consumed capsules in returned regimen bottles. At the end
of each visit participants are given a new regimen bottle
containing 45 capsules of their randomized regimen. All
women are given two regimen bottles containing 45 trial
supplements starting at the 32-week gestation study visit to
ensure an adequate supply for the period of delivery to the
first study visit at 6 weeks postpartum. Pregnant women
have a blood sample collected at 32 weeks gestation for as-
sessment of albumin-adjusted calcium. Pregnant women
with above the normal physiologic range of albumin-
adjusted calcium (>2.6 mmol/L) are diagnosed with hyper-
calcemia and immediately stop the trial regimen for the
duration of the study, and receive appropriate clinical
management.
Labor and delivery assessment
Study nurses/midwives are available throughout the day
and night to attend labor and delivery of participants.
Deliveries which occur outside of Dar es Salaam are
reached by phone to obtain relevant information from
the mother and/or clinic staff. During this visit women
and clinic staff are asked about any pregnancy complica-
tions since the last study visit and the duration of each
stage of labor and complications of labor are recorded.
Immediately after delivery, research midwives determine
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Apgar scores at 1 and 5 min. Length, weight, head cir-
cumference, chest circumference, and MUAC of the in-
fant are also taken in triplicate. Infant weight is
measured to the nearest 5 g using a digital scale (SECA,
Hamburg, Germany) and length with the use of a rigid
length board with an adjustable foot piece to 1-mm pre-
cision (SECA, Hamburg, Germany). Umbilical cord
blood samples and a heel prick dried blood spot are col-
lected from each infant.
Postnatal follow-up visits
Postnatal follow-up visits are integrated into standard
PMTCT visits. Mother/child pairs visit the clinic at 6, 10,
and 14 weeks postpartum and every month thereafter until
trial discharge at 1 year postpartum. At the postnatal visits
mothers receive a full clinical examination, have their WHO
HIV disease stage assessed, and all comorbidities are treated
in accordance with the Tanzanian standard of care. Nurses
also collect weight, MUAC, and blood pressure from
mothers. At the 6-month and 12-month postpartum visit
the baseline questionnaire on sociodemographic, depres-
sion, anxiety, social support, and physical activity is readmi-
nistered to mothers. All mothers have blood samples
collected at 6 weeks, 6 months, and 12 months postpartum
for assessment of albumin-adjusted calcium. Any mother
with above the normal physiologic range of albumin-
adjusted calcium (>2.6 mmol/L) is diagnosed with hypercal-
cemia and immediately stops the trial regimen for the
duration of the study, and receives appropriate clinical
management.
At postnatal visits infants receive a full clinical examin-
ation, have infant feeding practices assessed from the ma-
ternal report, and have morbidity history recorded with
the aid of a pictorial morbidity diary that mothers are
instructed to complete each day. The pictorial diary is
used to document the occurrence of diarrhea, common
cold, cough, difficulty breathing, fever, refusal to eat,
drink, or breastfeed, pus draining from ears, and vomit-
ing. At all study visits nurses also collect vaccination sta-
tus, infant vital signs (temperature, respiratory rate,
detection of chest indrawing, and blood pressure), and
record any outpatient clinic visits or hospitalizations since
the previous study visit. Study nurses also assess postpar-
tum infant weight with a digital infant balance scale to
the nearest 5 g (SECA, Hamburg, Germany) and length
to 1-mm precision with a rigid length board with an ad-
justable foot piece (SECA, Hamburg, Germany). All in-
fant anthropometric measurements are recorded in
triplicate. To assess HIV status, all infants receive an HIV
DNA PCR test at 6 weeks of age and then at 12 months
postpartum. All infants have serum samples and dried
blood spots stored for immunologic testing at 6 weeks,
6 months, and 1 year postpartum. At the trial discharge
visit, child cognitive, motor, language, and socioemotional
development will be assessed with the Caregiver-
Reported Early Development Index (CREDI) [43] .
Laboratory investigations
In order to examine the effect of the vitamin D3 regimen
on bone health, we will measure PTH in a 10% random
sample of women at randomization, 32 weeks gestation,
and then 6 weeks, 6 months, and 12 months postpartum.
A 10% sample of children will also have PTH assessed at
6 weeks, 6 months, and 12 months postpartum. We will
also assess the effect of vitamin D3 on maternal immune
responses through measurement of IL-2, IL-12, IFN-γ,
and cathelicidin in a random 10% sample of women at
randomization, 32 weeks gestation, and then 6 weeks,
6 months, and 12 months postpartum.
Adherence assessment
In order to promote adherence to the trial regimen, all
participants are encouraged to take the trial supplements
at the same time every day, to put the bottle in a visible
place, and identify an adherence assistant who would re-
mind her to take the supplement. Compliance with the
daily ToV5 supplements will be assessed in three ways
ways: 1) direct questioning about use of the supplements
in the previous 24 h and 2 weeks; 2) pill count from
returned daily regimen bottles; and 3) biochemical as-
sessment of 25(OH)D in a 10% subset of women longi-
tudinally at randomization, 32 weeks gestation, and then
6 weeks, 6 months, and 12 months postpartum.
Standard of care
All study women and children are provided with HIV care
and treatment that adhere to Tanzanian national PMTCT
guidelines. The first-line ART regimen for HIV-infected
pregnant women is tenofovir (TDF) + lamivudine (3TC) +
efavirenz (EFV), and alternative first-line regimens include
zidovudine (ZDV) + 3TC + EFV or ZDV+ 3TC + nevira-
pine (NVP) if not well tolerated. Women receive cotri-
moxazole prophylaxis if their CD4 T-cell count is < 200
cells/μL. Mothers receive daily iron (60 mg elemental) and
folate (400 μg) supplementation in pregnancy and two
doses of sulphadoxine pyremethamine (SP) are provided
for malaria prophylaxis at 20–24 weeks and 28–32 weeks
gestation. All infants will receive daily NVP from birth
through 6 weeks postpartum irrespective of the infant
feeding method. Cotrimoxazole prophylaxis is provided to
all infants beginning at 4–6 weeks postpartum and contin-
ued until HIV infection is excluded (6 weeks after cessa-
tion of breastfeeding). Infants are tested for HIV infection
at 6 weeks of age by PCR and, if negative, are retested
again with PCR at 12 months. HIV-infected infants initiate
ART regardless of WHO clinical stage or CD4 T-cell
count. The current first-line ART regimen for HIV-
infected children less than 3 years old in Tanzania is
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abacavir (ABC) + 3TC + lopinavir boosted by ritonavir
(LPV/r). All infants receive immunizations and high-dose
vitamin A supplementation (100,000 IU at 9 months) as
per standard of care.
Statistical analysis plan
An intent-to-treat analysis will be used as the primary
analytic strategy for all analyses. The primary efficacy trial
endpoints for the trial are: 1) maternal HIV progression or
death from any cause; 2) SGA births; and 3) infant stunt-
ing at 12 months of age. The primary safety endpoint is
maternal hypercalcemia. Maternal HIV progression will
be defined as any increase in WHO HIV disease stage
from the WHO HIV stage at randomization [39]. SGA will
be defined as a birth weight less than the tenth percentile
for gestational age by sex utilizing the Oken standard [29].
We acknowledge that the use of the last menstrual period
(LMP) for gestational age dating may lead to misclassifica-
tion of SGA [44]; nevertheless, errors in the maternal re-
port of LMP are expected to be nondifferential with
respect to the randomized regimen and therefore would
lead to underestimation of the effect of vitamin D supple-
ments on SGA. Stunting will be defined as LAZ which is 2
or more standard deviations below the WHO child growth
standard reference median [45]. Hypercalcemia will be de-
fined as an albumin-adjusted calcium > 2.6 mmol/L. We
will use the log-rank test stratified by study clinic to assess
differences in the incidence of maternal HIV progression
or death and use the binomial proportion test for SGA
births and child stunting at 12 months of age between the
treatment arms. The Fisher’s exact test will be used to as-
sess differences in the proportion of mothers with incident
hypercalcemia.
Secondary endpoints for the trial include: 1) postrandomi-
zation maternal CD4 T-cell count and post-randomization
HIV viral load; 2) postrandomization maternal immunologic
biomarker levels (IL-2, IL-12, IFN-γ, and cathelicidin); 3)
postrandomization maternal weight during pregnancy; 4)
maternal depression and anxiety as assessed by the HSCL;
5) maternal hypercalcemia (serum albumin adjusted cal-
cium > 2.6 mmol/L); 6) miscarriage; 7) stillbirth; 8) preterm
birth; 9) birthweight; 10) low birthweight (<2500 g); 11)
mother-to-child transmission of HIV; 12) infant mortality;
13) infant growth trajectory in the first year of life (LAZ,
WAZ, and WLZ); 14) infant wasting (WLZ <–2); 15) infant
underweight (WAZ<–2); 16) infant morbidities during the
first year of life; 17) postrandomization infant cognitive,
motor, and socioemotional development scores on the
CREDI; 18) serum 25(OH)D levels in the mother and in the
infant during the first 12 months of life; and 19) postrando-
mization maternal and infant PTH concentration. The bi-
nomial proportion test will be used for nonrepeatable
binomial secondary outcomes while generalized linear
mixed models with random intercepts, compound
symmetric covariance structures, and robust standard errors
will be used for repeated binomial secondary outcomes.
Linear mixed-effects models with a random intercept, a
compound symmetric covariance structure, and robust
standard errors will be used to assess the effect of the vita-
min D3 supplementation on the difference between baseline
and postrandomization of continuous secondary endpoints.
We will examine effect modification of any treatment ef-
fect by predefined baseline variables: maternal age, maternal
body mass index, socioeconomic status, gestational age at
randomization, CD4 T-cell count, hemoglobin concentra-
tion, WHO HIV disease stage, ART regimen, duration of
ART, duration of exclusive and any breastfeeding, and trial
regimen adherence. To assess the statistical significance of
each interaction, we will use the likelihood ratio test for
risk-ratio homogeneity for primary and secondary nonre-
peatable binomial outcomes and the score test in the linear
mixed-effects and generalized linear mixed models for re-
peatable binomial outcomes and continuous longitudinal
secondary outcomes.
Discussion
Antiretroviral therapy coverage for HIV-infected pregnant
women in sub-Saharan Africa continues to increase and is
accelerating due to implementation and planned roll-out of
Option B+ in the majority of high HIV burden countries
[2]. Provision of lifelong ART for all HIV-infected pregnant
women may nearly eliminate mother-to-child HIV transmis-
sion, but will also lead to exposure of about 1.5 million HEU
children every year to triple antiretrovirals in utero [5]. HIV-
exposed uninfected (HEU) infants are at increased risk of
mortality, and exposure to triple antiretrovirals in utero may
further increase the risk of small-for-gestational age births
and linear growth faltering [6–8, 12]. Accordingly, the ToV5
was designed to examine vitamin D3 supplementation as a
low-cost ART adjunct intervention which may improve ma-
ternal health, birth outcomes, and linear growth for HIV-
infected Tanzanian pregnant women and their children.
A search of clinicaltrials.gov determined the only other
clinical trial of vitamin D3 among HIV-infected individuals
with mortality, HIV progression, or morbidity as primary or
secondary outcomes is an ongoing study called the “Trial of
Vitamin D in HIV Progression” (NCT01798680). This trial
is also conducted by our research group and is a random-
ized, double-blind, placebo-controlled trial of vitamin D3
supplementation among HIV-infected men and nonpreg-
nant women conducted in Dar es Salaam, Tanzania. As a re-
sult, the ToV5 will likely be the first randomized trial to
determine the effect of vitamin D3 supplementation on
mortality and HIV disease progression among HIV-infected
pregnant women. An additional search determined at least
two trials of maternal vitamin D supplementation trials for
improvement of birth outcomes and child linear growth
that are ongoing or completed and to be published. A
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randomized trial of a maternal (4000 IU daily) and neonatal
(400 IU daily) vitamin D3 supplementation versus placebo
on maternal and neonatal complications was completed in
rural Pakistan and results are to be published
(NCT01229189). In addition a randomized, double blind,
placebo-controlled trial called the Maternal Vitamin D for
Infant Growth (MDIG) study is currently being conducted
in Dhaka, Bangladesh (NCT01924013) [46]. The primary
aims of the MDIG are to determine the effect of a range of
maternal vitamin D3 supplementation regimens in preg-
nancy (4200 IU/week, 16,800 IU/week, and 28,000 IU/
week) on infant length at 1 year as compared with placebo
and to determine the effect of a postpartum vitamin D3
regimen of 28,000 IU/week versus placebo on length at
1 year of age among infants of mothers who received
28,000 IU/week vitamin D3 during pregnancy. As a result,
we will likely be the first trial to examine the effect of vita-
min D supplementation on birth outcomes and linear
growth in the African context and for infants born to HIV-
infected mothers.
Overall, the ToV5 will provide causal evidence regarding
whether vitamin D3 should be considered as an ART ad-
junct intervention to improve maternal health, birth out-
comes, and linear growth for Tanzanian HIV-infected
pregnant women and their infants. The trial will also pro-
vide evidence for the effect of vitamin D3 supplementation
on a wide range of secondary maternal and child health
outcomes. The trial results will be communicated in aca-
demic journals and at the national and local levels in
Tanzania through policy briefs and dissemination meetings.
The results of ToV5 will likely be generalizable to HIV-
infected pregnant women and their children in similar
resource-limited settings utilizing the Option B+ approach.
Trial status
Trial enrollment started on 15 June 2015 and recruit-
ment is ongoing as of 30 July 2017.
Additional file
Additional file 1: Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) 2013 checklist. (PDF 131 kb)
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